Zhitong Finance App News, Quanxin Bio-B (02509.HK) issued an announcement. Recently, the results of the Chinese phase III clinical study on the treatment of prurigo nodularis (PN) with otokibizumab (QX005N) were successfully selected for the 35th Annual Meeting of the European Society of Dermatology and Venereology (EADV Congress 2026) in Vienna, Austria (EADV Congress 2026) and presented an oral report (Oral Oral) Presentation) format debut. The EADV annual conference is the largest in Europe and one of the most influential international conferences in the field of dermatology and venereology.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Quanxin Bio-B (02509.HK) issued an announcement. Recently, the results of the Chinese phase III clinical study on the treatment of prurigo nodularis (PN) with otokibizumab (QX005N) were successfully selected for the 35th Annual Meeting of the European Society of Dermatology and Venereology (EADV Congress 2026) in Vienna, Austria (EADV Congress 2026) and presented an oral report (Oral Oral) Presentation) format debut. The EADV annual conference is the largest in Europe and one of the most influential international conferences in the field of dermatology and venereology.